Pharmaceutical

Citius aims to bounce back from Lymphir setback

Citius Pharmaceuticals’ CEO detailed plans to launch its lymphoma therapy Lymphir in Autumn 2024, as it awaits a PDUFA date.

Mar 7, 2024 - 18:00
Citius aims to bounce back from Lymphir setback
Citius Pharmaceuticals’ CEO detailed plans to launch its lymphoma therapy Lymphir in Autumn 2024, as it awaits a PDUFA date.
Read the original article

Tags:

Previous Article

CTS Europe: The roadmap for generative AI in the pharma industry

Next Article

Sionna raises $182m to double down in cystic fibrosis drug development

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Filling 12-month prescriptions is one practical way to help the pharmacist crisis

Opinion: Filling 12-month prescriptions is one practica...

Nov 21, 2023

Tanden, Becerra, Califf make time for a meeting with tobacco lobbyists on the menthol ban

Tanden, Becerra, Califf make time for a meeting with to...

Nov 29, 2023

STAT+: Pharmalittle: We’re reading about LillyDirect, India’s drug standards, and more

STAT+: Pharmalittle: We’re reading about LillyDirect, I...

Jan 8, 2024